Global CAR T Cell Therapy Market and Clinical Trials Insight 2022

For Report Sample Contact: neeraj@kuickresearch.com

 

Report Weblink: https://www.kuickresearch.com/report-global-car-t-cell-therapy-market-and-clinical-trials-insight-2022.php

 

Table of Contents

 

1. Chimeric Antigen Receptor (CAR) T Cell Therapy – Next Era in Immuno Oncology

  1.1 Overview

  1.2 History and Development of CAR-T Technology

2. Evolution of Chimeric Antigen Receptor (CAR) T-Cell Design

  2.1 Structure of CAR T Cell

  2.2 1nd Generation Chimeric Antigen Receptor

  2.3 2nd and 3nd Generation CAR T Cell

3. Principle of Chimeric Antigen Receptor Design

  3.1 CAR Modified T Cells: Targeting

  3.2 CAR Modified T Cell: Signaling

4. CAR T Cell Therapies Delivery Pipeline and Mechanism of Action

  4.1 Process of CAR T Cell Therapy

  4.2 Mechanism of Action

5. Approaches to Improve the CAR T Cell Therapy

  5.1 Introduction

  5.2 Targeting the Tumor Stroma with CAR T Cells

  5.3 Targeting the Cytokine Networks

  5.4 Combination Strategies for CAR T Cells

  5.5 Targeting the Immune Checkpoints

6. Global CAR T Cell Therapy Clinical Trials for Cancer Treatment

  6.1 Acute Lymphoblastic Leukemia

  6.2 Multiple Myeloma

  6.3 Brain Tumors

  6.4 Lymphoma

  6.5 Solid Tumors

 

7. Global CAR T Cell Therapies Clinical Pipeline by Company, Indication and Phase

  7.1 Research

  7.2 Preclinical

  7.3 Clinical

  7.4 Phase-I

  7.5 Phase-I/II

  7.6 Phase-II

  7.7 Preregistration

8. Global Market Scenario of CAR T Cell Therapy

  8.1 Overview

  8.2 Estimated Price Analysis of CAR T Cell Therapy

9. Global Market Size of CAR T Cell Therapy

  9.1 Market Share of Cancer Immunotherapy by its Technology

  9.2 CAR T Cell Therapy Market Value

10. Global CAR T Cell Therapy Market Dynamics

  10.1 Favorable Parameters

  10.2 Challenges

11. Global CAR T Cell Therapy Market Future Prospects

12. Competitive Landscape

  12.1 Autolus

  12.2 Bellicum

  12.3 Bluebird

  12.4 Celgene

  12.5 Cellectis

  12.6 Celyad

  12.7 Eureka Therapeutics

  12.8 Fortress Biotech

  12.9 Immune Therapeutics

  12.10 Juno Therapeutics

  12.11 Kite Pharma

  12.12 Novartis

  12.13 Sorrento therapeutics

  12.14 TILT Biotherapeutics

  12.15 Ziopharm

 

Figure 1-1: Historical Development of CAR T Cell Therapy

Figure 2-1: Structure of Chimeric Antigen Receptor

Figure 2-2: First Generation Chimeric Antigen Receptor

Figure 2-3: Second Generation Chimeric Antigen Receptor

Figure 2-4: Third Generation Chimeric Antigen Receptor

Figure 3-1: Targeting Mechanism of Chimeric Antigen Receptor T-Cell

Figure 3-2: Signalling Mechanism of Chimeric Antigen Receptor T Cell

Figure 4-1: Delivery Pipeline of CAR T Cell Therapy Process

Figure 4-2: CAR T Cell Therapy Mechanism of Action

Figure 5-1: Strategies to Improve CAR T Cell Therapy

Figure 6-1: CAR T Cell Therapy in Brain Tumors

Figure 6-2: Chimeric Antigen Receptor Therapy in Lymphoma

Figure 6-3: Target of Cancer Cell by Chimeric Antigen Receptor

Figure 7-1: Global andndash; CAR T Cell Therapy Clinical Pipeline by Phase (Number), 2017-2022

Figure 7-2: Global andndash; CAR T Cell Therapy Clinical Pipeline by Phase (%), 2017-2022

Figure 8-1: Adoptive T-Cell Therapy – Open Clinical Trials to Investigate the Efficacy and Safety (%), 2015

Figure 8-2: Estimated Cost of T Cell Therapy and CAR T Cell Therapy Per Patient (US$)

Figure 9-1: Cancer Immunotherapy – Market Share of by Its Technology* (%)

Figure 9-2: Global Cancer Immunotherapeutic Market (US$ Billion), 2016-2022

Figure 9-3: Global – Predictive Market of CAR T Cell Therapeutics (US$ Million), 2016-2022

Figure 10-1: Favorable Market Parameters of CAR T Cell Therapy

Figure 10-2: Challenges to Market Growth of CAR T Cell Therapy

Figure 11-1: Future Potential Immuno-Oncology

Table 3-1: Antigens which are targeted by Chimeric Antigen Receptor

Table 12-1: Clinical Pipelines of Products